Vaccination of special populations: Protecting the vulnerable

Vaccine

Volumn 34, Issue 52, 2016, Pages 6681-6690

  Doherty, Mark ^a   Schmidt Ott, Ruprecht ^a   Santos, Jose Ignacio ^b   Stanberry, Lawrence R ^c,d   Hofstetter, Annika M ^e,f   Rosenthal, Susan L ^c   Cunningham, Anthony L ^g  

^a GSK   (Belgium)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^g Westmead Institute   (Australia)

Author keywords

Adolescent; Immunocompromised; Older adults; Pregnancy; Preterm; Special group

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ADVERSE OUTCOME; AGING; CHRONIC DISEASE; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOSENESCENCE; PREGNANCY; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; REVIEW; VACCINATION; VULNERABLE POPULATION; DISEASE TRANSMISSION; GLOBAL HEALTH; PREVENTION AND CONTROL; UTILIZATION;

DISEASE TRANSMISSION, INFECTIOUS; GLOBAL HEALTH; HUMANS; VACCINATION; VULNERABLE POPULATIONS;

EID: 85000900011     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.015     Document Type: Review

References (113)

1. [1] World Health Organization. Global Vaccine Action Plan 2011–2020, < http://www.who.int/immunization/global_vaccine_action_plan/en/> [accessed 20.04.16].
2. [2] Zenclussen, A.C., Adaptive immune responses during pregnancy. Am J Reprod Immunol 69 (2013), 291–303.
3. [3] Swamy, G.K., Heine, R.P., Vaccinations for pregnant women. Obstet Gynecol 125 (2015), 212–226.
4. [4] Creanga, A.A., Johnson, T.F., Graitcer, S.B., Hartman, L.K., Al-Samarrai, T., Schwarz, A.G., et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 115 (2010), 717–726.
5. [5] Webb, S.A., Pettila, V., Seppelt, I., Bellomo, R., Bailey, M., Cooper, D.J., et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 361 (2009), 1925–1934.
6. [6] World Health Organization. Summary of WHO position papers - recommendations for routine immunization. < http://www.who.int/immunization/policy/Immunization_routine_Table1.pdf?ua=1> [accessed 20.04.16].
7. [7] Swamy, G.K., Beigi, R.H., Maternal benefits of immunization during pregnancy. Vaccine 33 (2015), 6436–6440.
8. [8] Zaman, K., Roy, E., Arifeen, S.E., Rahman, M., Raqib, R., Wilson, E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 359 (2008), 1555–1564.
9. [9] Steinhoff, M.C., Omer, S.B., A review of fetal and infant protection associated with antenatal influenza immunization. Am J Obstet Gynecol, 207, 2012 S21-7.
10. [10] Kochhar, S., Rath, B., Seeber, L.D., Rundblad, G., Khamesipour, A., Ali, M., Introducing new vaccines in developing countries. Expert Rev Vaccines 12 (2013), 1465–1478.
11. [11] Thwaites, C.L., Beeching, N.J., Newton, C.R., Maternal and neonatal tetanus. Lancet 385 (2015), 362–370.
12. [12] Demicheli, V., Barale, A., Rivetti, A., Vaccines for women for preventing neonatal tetanus. Cochrane Database Syst Rev, 7, 2015, CD002959.
13. [13] World Health Organization. Maternal and Neonatal Tetanus (MNT) elimination, http://www.who.int/immunization/diseases/MNTE_initiative/en/ [accessed 20.04.16].
14. [14] Nitsch-Osuch, A., Korzeniewski, K., Gawlak, M., Zycinska, K., Wardyn, K., Kuchar, E., Epidemiological and clinical reasons for vaccination against pertussis and influenza in pregnant women. Adv Exp Med Biol 849 (2015), 11–21.
15. [15] Advisory Committee on Immunization Practices, Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women–Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 62 (2013), 131–135.
16. [16] World Health Organization, Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec 90 (2015), 433–458.
17. [17] Safadi, M.A., Control of pertussis in infants: time has finally come?. Expert Rev Vaccines 14 (2015), 781–783.
18. [18] Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S., Kara, E., Donegan, K., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384 (2014), 1521–1528.
19. [19] Wilson, R.J., Paterson, P., Jarrett, C., Larson, H.J., Understanding factors influencing vaccination acceptance during pregnancy globally: a literature review. Vaccine 33 (2015), 6420–6429.
20. [20] Goldkind, S.F., Sahin, L., Gallauresi, B., Enrolling pregnant women in research–lessons from the H1N1 influenza pandemic. N Engl J Med 362 (2010), 2241–2243.
21. [21] Kharbanda, E.O., Vazquez-Benitez, G., Lipkind, H.S., Klein, N.P., Cheetham, T.C., Naleway, A., et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA 312 (2014), 1897–1904.
22. [22] Donegan, K., King, B., Bryan, P., Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ, 349, 2014, g4219.
23. [23] Ding, H., Black, C.L., Ball, S., Donahue, S., Izrael, D., Williams, W.W., et al. Influenza vaccination coverage among pregnant women–United States, 2013–14 influenza season. MMWR Morb Mortal Wkly Rep 63 (2014), 816–821.
24. [24] Healy, C.M., Rench, M.A., Montesinos, D.P., Ng, N., Swaim, L.S., Knowledge and attitudes of pregnant women and their providers towards recommendations for immunization during pregnancy. Vaccine 33 (2015), 5445–5451.
25. [25] Public Health England. Influenza immunisation programme for England. GP patient groups. Data collection survey. Season 2015 to 2016, < https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/544552/Seasonal_flu_GP_patient_groups_annual_report_2015_2016.pdf> [accessed 05.10.16].
26. [26] Public Health England. Pertussis vaccination programme for pregnant women update: vaccine coverage in England, January to March 2016, < https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/526208/hpr1816_prntl-prtsss.pdf> [accessed 05.10.16].
27. [27] World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2016 global summary. < http://apps.who.int/immunization_monitoring/globalsummary/> [accessed 05.10.16].
28. [28] Bonanni, P., Di Pasquale, A., Garçon, N., Stanberry, L., El-Hodhod, M., Cheng, W.F., et al. Evaluation of vaccine safety: practical aspects in assessing benefits and risks. Vaccine, XX, 2016 ZZ-ZZ.
29. [29] Esposito, S., Fumagalli, M., Principi, N., Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 11 (2012), 1199–1209.
30. [30] Langkamp, D.L., Davis, J.P., Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight children. J Pediatr 128 (1996), 654–659.
31. [31] Mahon, B.E., Ehrenstein, V., Norgaard, M., Pedersen, L., Rothman, K.J., Sorensen, H.T., Perinatal risk factors for hospitalization for pneumococcal disease in childhood: a population-based cohort study. Pediatrics, 119, 2007 e804-12.
32. [32] Ladhani, S.N., Ramsay, M.E., Timely immunisation of premature infants against rotavirus in the neonatal intensive care unit. Arch Dis Child Fetal Neonatal Ed, 99, 2014 F445-7.
33. [33] Advisory Committee on Immunization Practices. Hepatitis B immunization management of preterm infants weighing <2,000 g, by maternal hepatitis B surface antigen (HBsAg) status, < http://www.cdc.gov/hepatitis/hbv/pdfs/correctedtable4.pdf> [accessed 20.04.16].
34. [34] World Health Organization, Pneumococcal vaccines WHO position paper–2012. Wkly Epidemiol Rec 87 (2012), 129–144.
35. [35] Omeñaca, F., Merino, J.M., Tejedor, J.C., Constantopoulos, A., Papaevangelou, V., Kafetzis, D., et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics, 128, 2011 e290-8.
36. [36] Crawford, N.W., Yeo, V., Hunt, R.W., Barfield, C., Gelbart, B., Buttery, J.P., Immunisation practices in infants born prematurely: neonatologists’ survey and clinical audit. J Paediatr Child Health 45 (2009), 602–609.
37. [37] Crawford, N.W., Barfield, C., Hunt, R.W., Pitcher, H., Buttery, J.P., Improving preterm infants’ immunisation status: a follow-up audit. J Paediatr Child Health 50 (2014), 314–318.
38. [38] Monk, H.M., Motsney, A.J., Wade, K.C., Safety of rotavirus vaccine in the NICU. Pediatrics, 133, 2014 e1555-60.
39. [39] Stumpf, K.A., Thompson, T., Sanchez, P.J., Rotavirus vaccination of very low birth weight infants at discharge from the NICU. Pediatrics, 132, 2013 e662-5.
40. [40] Thrall, S., Doll, M.K., Nhan, C., Gonzales, M., Perreault, T., Lamer, P., et al. Evaluation of pentavalent rotavirus vaccination in neonatal intensive care units. Vaccine 33 (2015), 5095–5102.
41. [41] Navar-Boggan, A.M., Halsey, N.A., Escobar, G.J., Golden, W.C., Klein, N.P., Underimmunization at discharge from the neonatal intensive care unit. J Perinatol 32 (2012), 363–367.
42. [42] Miller, M.A., Rathore, M.H., Immunization in special populations. Adv Pediatr 59 (2012), 95–136.
43. [43] Rubin, L.G., Levin, M.J., Ljungman, P., Davies, E.G., Avery, R., Tomblyn, M., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58 (2014), 309–318.
44. [44] Perry, L.M., Winthrop, K.L., Curtis, J.R., Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep, 16, 2014, 431.
45. [45] Chaudrey, K., Salvaggio, M., Ahmed, A., Mahmood, S., Ali, T., Updates in vaccination: recommendations for adult inflammatory bowel disease patients. World J Gastroenterol 21 (2015), 3184–3196.
46. [46] Advisory Committee on Immunization Practices, General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60 (2011), 1–64.
47. [47] Pearson-Stuttard, J., Blundell, S., Harris, T., Cook, D.G., Critchley, J., Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol 4 (2016), 148–158.
48. [48] Malfroot, A., Adam, G., Ciofu, O., Doring, G., Knoop, C., Lang, A.B., et al. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 4 (2005), 77–87.
49. [49] Advisory Committee on Immunization Practices, Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 52 (2003), 739–740.
50. [50] Oreja-Guevara, C., Wiendl, H., Kieseier, B.C., Airas, L., Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. Ther Adv Neurol Disord 7 (2014), 137–149.
51. [51] Smith, C., Khanna, R., Immune regulation of human herpesviruses and its implications for human transplantation. Am J Transplant 13:Suppl 3 (2013), 9–23.
52. [52] McDonald-Hyman, C., Turka, L.A., Blazar, B.R., Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med, 7, 2015, 280rv2.
53. [53] Ma, C.K., Blyth, E., Clancy, L., Simms, R., Burgess, J., Brown, R., et al. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. Cytotherapy 17 (2015), 1406–1420.
54. [54] Kuchar, E., Miskiewicz, K., Karlikowska, M., A review of guidance on immunization in persons with defective or deficient splenic function. Br J Haematol 171 (2015), 683–694.
55. [55] Davidson, R.N., Wall, R.A., Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 7 (2001), 657–660.
56. [56] Smith, S.A., Poland, G.A., Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 23 (2000), 95–108.
57. [57] Advisory Committee on Immunization Practices, Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013–2014. MMWR Recomm Rep 62 (2013), 1–43.
58. [58] European Centre for Disease Prevention and Control. Guidance. Priority risk groups for influenza vaccination. < http://ecdc.europa.eu/en/publications/Publications/0808_GUI_Priority_Risk_Groups_for_Influenza_Vaccination.pdf> [accessed 20.04.16].
59. [59] Advisory Committee on Immunization Practices, Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 59 (2010), 1102–1106.
60. [60] Schillie, S.F., Xing, J., Murphy, T.V., Hu, D.J., Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999–2010. J Viral Hepat 19 (2012), 674–676.
61. [61] Reilly, M.L., Schillie, S.F., Smith, E., Poissant, T., Vonderwahl, C.W., Gerard, K., et al. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus. J Diabetes Sci Technol 6 (2012), 858–866.
62. [62] Huang, Y.W., Wang, T.C., Lin, S.C., Chang, H.Y., Chen, D.S., Hu, J.T., et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis 57 (2013), 1695–1702.
63. [63] Guignard, A.P., Greenberg, M., Lu, C., Rosillon, D., Vannappagari, V., Risk of herpes zoster among diabetics: a matched cohort study in a US insurance claim database before introduction of vaccination, 1997–2006. Infection 42 (2014), 729–735.
64. [64] Suaya, J.A., Chen, S.Y., Li, Q., Burstin, S.J., Levin, M.J., Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. Open Forum Infect Dis., 1, 2014, ofu049.
65. [65] Weitzman, D., Shavit, O., Stein, M., Cohen, R., Chodick, G., Shalev, V., A population based study of the epidemiology of Herpes Zoster and its complications. J Infect 67 (2013), 463–469.
66. [66] Forbes, H.J., Thomas, S.L., Smeeth, L., Clayton, T., Farmer, R., Bhaskaran, K., et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 157 (2016), 30–54.
67. [67] Advisory Committee on Immunization Practices, Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 60 (2011), 1709–1711.
68. [68] Shea, K.M., Edelsberg, J., Weycker, D., Farkouh, R.A., Strutton, D.R., Pelton, S.I., Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis, 1, 2014, ofu024.
69. [69] Masson, A., Launay, O., Delaisi, B., Bassinet, L., Remus, N., Lebourgeois, M., et al. Vaccine coverage in CF children: a French multicenter study. J Cyst Fibros 14 (2015), 615–620.
70. [70] Alcusky, M.J., Pawasauskas, J., Adherence to guidelines for hepatitis B, pneumococcal, and influenza vaccination in patients with diabetes. Clin Diabetes 33 (2015), 116–122.
71. [71] Dempsey, A.F., Zimet, G.D., Interventions to improve adolescent vaccination: what may work and what still needs to be tested. Am J Prev Med, 49, 2015 S445-54.
72. [72] Gottlieb, S.L., Low, N., Newman, L.M., Bolan, G., Kamb, M., Broutet, N., Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine 32 (2014), 1527–1535.
73. [73] Sawyer, S.M., Drew, S., Yeo, M.S., Britto, M.T., Adolescents with a chronic condition: challenges living, challenges treating. Lancet 369 (2007), 1481–1489.
74. [74] Hofstetter, A.M., LaRussa, P., Rosenthal, S.L., Vaccination of adolescents with chronic medical conditions: special considerations and strategies for enhancing uptake. Hum Vaccin Immunother 11 (2015), 2571–2581.
75. [75] Strikas, R.A., Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years–United States, 2015. MMWR Morb Mortal Wkly Rep 64 (2015), 93–94.
76. [76] Broder, K.R., Cortese, M.M., Iskander, J.K., Kretsinger, K., Slade, B.A., Brown, K.H., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 (2006), 1–34.
77. [77] Cohn, A.C., MacNeil, J.R., Clark, T.A., Ortega-Sanchez, I.R., Briere, E.Z., Meissner, H.C., et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 62 (2013), 1–28.
78. [78] World Health Organization, Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 86 (2011), 521–539.
79. [79] Advisory Committee on Immunization Practices, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 62 (2013), 521–524.
80. [80] Klosky, J.L., Russell, K.M., Canavera, K.E., Gammel, H.L., Hodges, J.R., Foster, R.H., et al. Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer. Cancer Prev Res (Phila) 6 (2013), 1101–1110.
81. [81] Hoffman, L., Okcu, M.F., Dreyer, Z.E., Suzawa, H., Bryant, R., Middleman, A.B., Human papillomavirus vaccination in female pediatric cancer survivors. J Pediatr Adolesc Gynecol 25 (2012), 305–307.
82. [82] Pebody, R.G., Hippisley-Cox, J., Harcourt, S., Pringle, M., Painter, M., Smith, G., Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999–2005. Epidemiol Infect 136 (2008), 360–369.
83. [83] Pandolfi, E., Carloni, E., Marino, M.G., Ciofi degli Atti, M.L., Gesualdo, M., Romano, M., et al. Immunization coverage and timeliness of vaccination in Italian children with chronic diseases. Vaccine 30 (2012), 5172–5178.
84. [84] Britto, M.T., Garrett, J.M., Dugliss, M.A., Johnson, C.A., Majure, J.M., Leigh, M.W., Preventive services received by adolescents with cystic fibrosis and sickle cell disease. Arch Pediatr Adolesc Med 153 (1999), 27–32.
85. [85] Hofstetter, A.M., Rosenthal, S.L., Factors impacting HPV vaccination: lessons for health care professionals. Expert Rev Vaccines 13 (2014), 1013–1026.
86. [86] Pera, A., Campos, C., Lopez, N., Hassouneh, F., Alonso, C., Tarazona, R., et al. Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas 82 (2015), 50–55.
87. [87] Kim, D.K., Bridges, C.B., Harriman, K.H., Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older–United States, 2015. MMWR Morb Mortal Wkly Rep 64 (2015), 91–92.
88. [88] World Health Organization, Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 87 (2012), 461–476.
89. [89] Morrill, H.J., Caffrey, A.R., Noh, E., LaPlante, K.L., Epidemiology of pneumococcal disease in a national cohort of older adults. Infect Dis Ther 3 (2014), 19–33.
90. [90] Tomczyk, S., Bennett, N.M., Stoecker, C., Gierke, R., Moore, M.R., Whitney, C.G., et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ⩾65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63 (2014), 822–825.
91. [91] Bonten, M.J., Huijts, S.M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372 (2015), 1114–1125.
92. [92] Levin, M.J., Smith, J.G., Kaufhold, R.M., Barber, D., Hayward, A.R., Chan, C.Y., et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188 (2003), 1336–1344.
93. [93] Weinberg, A., Lazar, A.A., Zerbe, G.O., Hayward, A.R., Chan, I.S., Vessey, R., et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis 201 (2010), 1024–1030.
94. [94] Oxman, M.N., Levin, M.J., Johnson, G.R., Schmader, K.E., Straus, S.E., Gelb, L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005), 2271–2284.
95. [95] Morrison, V.A., Johnson, G.R., Schmader, K.E., Levin, M.J., Zhang, J.H., Looney, D.J., et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 60 (2015), 900–909.
96. [96] Harpaz, R., Ortega-Sanchez, I.R., Seward, J.F., Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57 (2008), 1–30.
97. [97] Lal, H., Cunningham, A.L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.J., et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372 (2015), 2087–2096.
98. [98] Cunningham, A.L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.J., Diez-Domingo, J., et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375 (2016), 1019–1032.
99. [99] Palache, A., Oriol-Mathieu, V., Fino, M., Xydia-Charmanta, M., Seasonal influenza vaccine dose distribution in 195 countries (2004–2013): little progress in estimated global vaccination coverage. Vaccine 33 (2015), 5598–5605.
100. [100] Centers for Disease Control and Prevention. Flu vaccination coverage. United States, 2014-15 influenza season. < http://www.cdc.gov/flu/fluvaxview/coverage-1415estimates.htm> [accessed 20.04.16].
101. [101] Williams, W.W., Lu, P.J., O'Halloran, A., Bridges, C.B., Kim, D.K., Pilishvili, T., et al. Vaccination coverage among adults, excluding influenza vaccination - United States, 2013. MMWR Morb Mortal Wkly Rep 64 (2015), 95–102.
102. [102] Eilers, R., Krabbe, P.F., de Melker, H.E., Factors affecting the uptake of vaccination by the elderly in Western society. Prev Med 69 (2014), 224–234.
103. [103] Swanson, K.A., Schmitt, H.J., Jansen, K.U., Anderson, A.S., Adult vaccination. Hum Vaccin Immunother 11 (2015), 150–155.
104. [104] Lefebvre, J.S., Haynes, L., Vaccine strategies to enhance immune responses in the aged. Curr Opin Immunol 25 (2013), 523–528.
105. [105] Verma, R., Khanna, P., Chawla, S., Vaccines for the elderly need to be introduced into the immunization program in India. Hum Vaccin Immunother 10 (2014), 2468–2470.
106. [106] Breteler, J.K., Tam, J.S., Jit, M., Ket, J.C., De Boer, M.R., Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: a systematic review and meta-analysis. Vaccine 31 (2013), 5168–5177.
107. [107] Dwyer, D., Barr, I., Hurt, A., Kelso, A., Reading, P., Sullivan, S., et al. Seasonal influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region. Western Pac Surveill Response J 4 (2013), 51–59.
108. [108] PAHO. PAHO's regional immunization vision and strategy 2007-2015, < http://www.who.int/immunization/sage/PAHO_RIVS.pdf> [accessed 20.04.16].
109. [109] Thomas, R.E., Lorenzetti, D.L., Interventions to increase influenza vaccination rates of those 60 years and older in the community. Cochrane Database Syst Rev, 2014, CD005188.
110. [110] Jacobson Vann, J.V., Szilagyi, P., Patient reminder and patient recall systems to improve immunization rates. Cochrane Database Syst Rev, 2005, CD003941.
111. [111] Oyo-Ita, A., Wiysonge, C.S., Oringanje, C., Nwachukwu, C.E., Oduwole, O., Meremikwu, M.M., Interventions for improving coverage of childhood immunisation in low- and middle-income countries. Cochrane Database Syst Rev, 7, 2016, CD008145.
112. [112] Bangure, D., Chirundu, D., Gombe, N., Marufu, T., Mandozana, G., Tshimanga, M., et al. Effectiveness of short message services reminder on childhood immunization programme in Kadoma, Zimbabwe - a randomized controlled trial, 2013. BMC Public Health, 15, 2015, 137.
113. [113] Gibson, D.G., Kagucia, E.W., Ochieng, B., Hariharan, N., Obor, D., Moulton, L.H., et al. The Mobile Solutions for Immunization (M-SIMU) trial: a protocol for a cluster randomized controlled trial that assesses the impact of mobile phone delivered reminders and travel subsidies to improve childhood immunization coverage rates and timeliness in Western Kenya. JMIR Res Protoc, 5, 2016, e72.